title: Coagulation system activated in Duchenne muscular dystrophy patients with cardiac dysfunction.
abstract: We investigated basic abnormalities of coagulation and fibrinolysis in Duchenne muscular dystrophy (DMD) patients with cardiac dysfunction. Forty seven patients with DMD, aged 13-37 years old, were enrolled. Based on left ventricular ejection fraction (LVEF) results determined by echocardiography, patients were divided into 3 groups: LVEF less than 30% (markedly depressed group), LVEF between 30 and 50% (slightly depressed), and LVEF greater than 50% (normal). We measured serum levels of total fibrin and fibrinogen degradation products (FDP), as well as plasma fibrinogen, thrombin-antithrombin complex (TAT), prothrombin fragment (F1+2), and D-dimer. The levels of TAT and F1+2 in the markedly depressed group were significantly elevated compared with the other groups, whereas FDP, fibrinogen, and D-dimer levels did not differ among the groups. We concluded that activated coagulation is associated with cardiac dysfunction in patients with DMD.
authors.affiliation: Division of Neurology, National Hospital Organization Toneyama National Hospital, 5-1-1 Toneyama, Toyonaka, Osaka 560-8552, Japan. saitot@toneyama.hosp.go.jp
authors.forename: Toshio
authors.initials: T
authors.lastname: Saito
authors.forename: Yuko
authors.initials: Y
authors.lastname: Yamamoto
authors.forename: Tsuyoshi
authors.initials: T
authors.lastname: Matsumura
authors.forename: Sonoko
authors.initials: S
authors.lastname: Nozaki
authors.forename: Harutoshi
authors.initials: H
authors.lastname: Fujimura
authors.forename: Susumu
authors.initials: S
authors.lastname: Shinno
mesh_terms: D000293:Adolescent; D000328:Adult; D000990:Antithrombin III; D001778:Blood Coagulation Disorders / Q000097:blood / Q000150:complications*; D002311:Cardiomyopathy, Dilated / Q000097:blood / Q000150:complications* / Q000000981:diagnostic imaging; D003328:Coronary Thrombosis / Q000097:blood / Q000150:complications*; D004452:Echocardiography; D005338:Fibrin Fibrinogen Degradation Products / Q000378:metabolism; D005340:Fibrinogen / Q000378:metabolism; D005342:Fibrinolysis; D006801:Humans; D008297:Male; D020388:Muscular Dystrophy, Duchenne / Q000097:blood / Q000150:complications*; D010446:Peptide Fragments / Q000097:blood; D010447:Peptide Hydrolases / Q000097:blood; D011498:Protein Precursors / Q000097:blood; D011516:Prothrombin
chemical_list: D005338:Fibrin Fibrinogen Degradation Products; D010446:Peptide Fragments; D011498:Protein Precursors; C046193:antithrombin III-protease complex; C036309:fibrin fragment D; C029733:prothrombin fragment 1; C044183:prothrombin fragment 2; D000990:Antithrombin III; D011516:Prothrombin; D005340:Fibrinogen; D010447:Peptide Hydrolases